Appl. No.: 09/954,764 Filed: September 18, 2001

Page 3

REMARKS

The amendment to the specification at page 29, line 4, merely corrects a typographical error that was introduced in the amendment to this line in the response filed March 29, 2004, wherein the ATCC deposit number for the hybridoma cell line secreting the 3A8 antibody was incorrectly amended to read "HB 120124" instead of "HB 12024." As evidenced in the ATTC deposit contracts previously made of record in the RCE filed July 29, 2004, the amendment to the deposit number to correctly reflect the "HB 12024" designation adds no new matter. Accordingly, entry of this correction of the typographical error is respectfully requested so that the patent can issue with the correct deposit information.

Comments on Statement for Reasons for Allowance

Applicants also take this opportunity to respond to the Examiner's comments in the Reasons for Allowance provided with the Notice of Allowance. The Examiner has assigned May 28, 1993 as the filing date for the subject matter recited in the claims issuing in the present application. It is the Examiner's opinion that the earliest priority application, U.S. Serial No. 07/910,222, filed July 9, 1992 (not 2002 as indicated in the Reasons for Allowance) does not provide sufficient written support for the claimed methods of treating IgE-mediated allergic diseases with the claimed antibodies.

The anti-CD40 antibodies designated 5D12, 3C6, and 3A8, which are recited in the issuing claims, and methods of making these antibodies were disclosed in the original priority document. See Example 6, Table 2, and Example 7 of U.S. Serial No. 07/910,222. In addition, methods of using these antibodies as anti-viral agents and as a means of enhancing an anti-viral immune response were also disclosed. Therefore Applicants are entitled to the July 9, 1992 priority date for the issuing claims.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required

Appl. No.: 09/954,764 Filed: September 18, 2001

Page 4

therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 03-1664.

Respectfully submitted,

Roc Alexaner

Lisa E. Alexander Attorney for Applicants

Registration No. 41,576

Customer No. 27476 CHIRON CORPORATION

Intellectual Property
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-2585
(510) 655-3542 (fax)

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number EV 351 354 898 US Date of Deposit January 21, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX ISSUE FEE, Commissioner for Patents, P.O. Box

1450, Alexandria, VA 22313-1450

Esperanza C. Licad